Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180671 | 0.92 | KDM4E (0.54) | CXCR2KDM4ESGMS2MRGPRX4MAPT | |
| SCHEMBL485652 | 0.84 | CXCR2 (0.54) | CXCR2KDM4EMRGPRX4MAPT | |
| SCHEMBL484856 | 0.83 | CXCR2 (0.52) | CXCR2KDM4EMRGPRX4HPGDSCN9A | |
| SCHEMBL485704 | 0.83 | CXCR2 (0.52) | CXCR2KDM4EMRGPRX4 | |
| SCHEMBL485633 | 0.81 | CXCR2 (0.51) | CXCR2KDM4EMRGPRX4 | |
| SCHEMBL485011 | 0.81 | CXCR2 (0.54) | CXCR2KDM4EMRGPRX4MAPTTDP1 | |
| SCHEMBL485484 | 0.81 | CXCR2 (0.49) | CXCR2KDM4EMRGPRX4MAPTHPGD | |
| SCHEMBL485535 | 0.79 | MRGPRX4 (0.46) | CXCR2KDM4EMRGPRX4HPGD | |
| SCHEMBL485456 | 0.78 | CXCR2 (0.49) | CXCR2KDM4EMRGPRX4MAPTHPGD | |
| SCHEMBL485203 | 0.78 | CXCR2 (0.49) | CXCR2KDM4EMRGPRX4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836158-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-26 | — | — | EP | claimed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | claimed |
| EP-1836158-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |